Larry Robbins' portfolio
Healthcare and consumer-focused long/short with event catalysts.
What changed in Q2 2026
Compared with the previous 13F. Values are as reported at quarter end. How to read a 13F.
New positions
- Agilent TechnologiesA$277M
- SPYSPY$194M
- Eli Lilly andLLY$69M
- MKS InstrumentsMKSI$44M
- STMicroelectronics NV ADRSTM$42M
- AbbVieABBV$37M
- AstraZenecaAZN$35M
- Elevance HealthELV$26M
- Microchip TechnologyMCHP$24M
- BrukerBRKR$15M
Added to
- Global PaymentsGPN$646M
- Tenet HealthcareTHC$418M
- Thermo Fisher ScientificTMO$314M
- Amazon.comAMZN$303M
- Meta PlatformsMETA$201M
- ViatrisVTRS$157M
- Uber TechnologiesUBER$129M
- Dick’s Sporting GoodsDKS$91M
- Genius SportsGENI$82M
- National VisionEYE$59M
Trimmed
- CVS HealthCVS$499M
- Advanced Micro DevicesAMD$173M
- Teva Pharma Industries Ltd ADRTEVA$172M
- CenteneCNC$121M
- CignaCI$114M
- HumanaHUM$101M
- BlockXYZ$91M
- Onto InnovationONTO$78M
- Element SolutionsESI$47M
- Applied MaterialsAMAT$47M
Sold out
None this quarter.
Holdings
44 US-listed positions in the Q2 2026 13F, largest first.
| Stock | % of portfolio | Value | Shares | Last quarter |
|---|---|---|---|---|
| Global PaymentsGPN | 11.77% | $646M | 8,906,709 | Added |
| CVS HealthCVS | 9.09% | $499M | 4,824,799 | Trimmed |
| Tenet HealthcareTHC | 7.62% | $418M | 2,235,666 | Added |
| Thermo Fisher ScientificTMO | 5.73% | $314M | 627,240 | Added |
| Amazon.comAMZN | 5.52% | $303M | 1,271,687 | Added |
| Agilent TechnologiesA | 5.05% | $277M | 2,086,141 | New |
| Ishares Tr | 5.02% | $276M | 918,200 | Held |
| Danaher Corp Del | 3.98% | $218M | 1,145,979 | Held |
| Meta PlatformsMETA | 3.66% | $201M | 356,841 | Added |
| SPYSPY | 3.54% | $194M | 260,000 | New |
| Advanced Micro DevicesAMD | 3.16% | $173M | 298,410 | Trimmed |
| Teva Pharma Industries Ltd ADRTEVA | 3.13% | $172M | 5,081,091 | Trimmed |
| ViatrisVTRS | 2.86% | $157M | 9,877,409 | Added |
| Uber TechnologiesUBER | 2.36% | $129M | 1,793,598 | Added |
| CenteneCNC | 2.21% | $121M | 1,886,055 | Trimmed |
| Butterfly NetworkBFLY | 2.20% | $121M | 14,335,055 | Held |
| CignaCI | 2.07% | $114M | 412,223 | Trimmed |
| HumanaHUM | 1.84% | $101M | 254,216 | Trimmed |
| BlockXYZ | 1.66% | $91M | 1,197,046 | Trimmed |
| Dick’s Sporting GoodsDKS | 1.66% | $91M | 401,067 | Added |
| Genius SportsGENI | 1.49% | $82M | 13,495,287 | Added |
| Onto InnovationONTO | 1.42% | $78M | 205,791 | Trimmed |
| Eli Lilly andLLY | 1.26% | $69M | 57,771 | New |
| United Airls Hldgs | 1.23% | $67M | 494,736 | Held |
| National VisionEYE | 1.07% | $59M | 3,101,083 | Added |
| Cisco SystemsCSCO | 0.88% | $49M | 413,332 | Added |
| Element SolutionsESI | 0.86% | $47M | 994,579 | Trimmed |
| Applied MaterialsAMAT | 0.86% | $47M | 65,201 | Trimmed |
| MKS InstrumentsMKSI | 0.80% | $44M | 98,532 | New |
| Six Flags EntertainmentFUN | 0.78% | $43M | 2,017,821 | Trimmed |
| STMicroelectronics NV ADRSTM | 0.76% | $42M | 560,060 | New |
| AbbVieABBV | 0.68% | $37M | 148,913 | New |
| AstraZenecaAZN | 0.64% | $35M | 184,279 | New |
| Bausch Plus Lomb | 0.58% | $32M | 1,918,148 | Held |
| Baker HughesBKR | 0.50% | $27M | 493,519 | Added |
| Elevance HealthELV | 0.47% | $26M | 66,599 | New |
| Microchip TechnologyMCHP | 0.44% | $24M | 265,577 | New |
| BrukerBRKR | 0.28% | $15M | 252,169 | New |
| Novartis AG ADRNVS | 0.25% | $14M | 86,909 | New |
| DigitalOceanDOCN | 0.24% | $13M | 84,812 | Trimmed |
| Primo BrandsPRMB | 0.18% | $10M | 404,971 | Trimmed |
| Boston ScientificBSX | 0.09% | $5M | 113,096 | New |
| Cardinal HealthCAH | 0.08% | $4M | 18,018 | New |
| Bio-TechneTECH | 0.07% | $4M | 58,324 | Trimmed |
By sector
Share of the reported value.
Reported value over time
Total 13F value at each quarter end.
Questions
What stocks does Larry Robbins own?
In the Q2 2026 13F, Glenview Capital Management reported 44 US stock positions worth $5.5B. The largest: Global Payments (GPN) 11.8%, CVS Health (CVS) 9.1%, Tenet Healthcare (THC) 7.6%, Thermo Fisher Scientific (TMO) 5.7%, Amazon.com (AMZN) 5.5%.
What did Larry Robbins buy last quarter?
In Q2 2026: new position in Agilent Technologies (A); new position in SPY (SPY); new position in Eli Lilly and (LLY); added to Global Payments (GPN); added to Tenet Healthcare (THC); added to Thermo Fisher Scientific (TMO).
When is Larry Robbins's next 13F?
13F filings are due 45 days after each quarter ends. The Q3 2026 filing is due by November 14, 2026.
More investors
13F filings list US-listed long positions (and some options) held at quarter end. They leave out short positions, cash, bonds and non-US holdings, and arrive up to 45 days after the quarter ends, so the investor may have traded since. Information only, not investment advice.